A federal appeals court handed pro-life advocates a major legal victory Friday, blocking the mail-order distribution of the abortion pill mifepristone and reinstating in-person dispensing requirements that the Biden administration systematically dismantled.
The unanimous decision from the 5th U.S. Circuit Court of Appeals halts a Biden-era policy that allowed the drug to be prescribed via telehealth and shipped by mail, a system the administration aggressively expanded following the Supreme Court’s 2022 decision in Dobbs v. Jackson Women’s Health Organization. The court acknowledged the ruling will have broad consequences, noting it would “as a practical matter, have a nationwide effect.”
“The public interest is not served by perpetuating a medical practice whose safety the agency admits was inadequately studied. Indeed, the public interest demands the opposite.”
The case was brought by Louisiana, which argued that federal policy allowing mail-order abortions was a direct assault on its sovereign authority to protect unborn life. The state also cited tens of thousands of dollars in Medicaid spending tied to emergency care for complications from the drug. The court agreed, finding the harm to state sovereignty irreversible.
“Every abortion facilitated by FDA’s action cancels Louisiana’s ban. Once lost, that sovereign prerogative of protecting unborn life cannot be regained.”
Judges were sharply critical of the FDA’s handling of safety data, pointing to a particularly damning sequence: the agency had previously eliminated requirements to report mifepristone’s adverse events, then turned around and cited the resulting lack of data as justification for expanding access. The court called that reasoning “unreasonable.” The panel concluded Louisiana is strongly likely to succeed on the merits of its challenge and is suffering irreparable harm while the policy remains in effect.
Mifepristone, typically used in combination with a second drug, accounts for a majority of abortions in the United States. Under the Biden-era mail-order regime, the drug reached even states with strict abortion bans, with Louisiana documenting nearly 1,000 illegal chemical abortions per month occurring within its borders as a direct result of the federal policy. That put the drug at the center of post-Dobbs legal fights, as pro-life states moved to close what they described as a federal loophole undermining their abortion laws.
Pro-life leaders swiftly praised the ruling as a long-overdue restoration of patient safety standards.
“Women deserve better than an abortion-by-mail system that prioritizes ideology over safety,” said National Right to Life Committee President Carol Tobias.
Susan B. Anthony Pro-Life America President Marjorie Dannenfelser echoed that sentiment, calling it “a huge victory for victims and survivors,” arguing that eliminating in-person requirements had led to predictable harms for women and unborn children.
“This is a win we’ve been waiting for, and we pray it holds,” Students for Life President Kristan Hawkins added.
Abortion advocates and Democratic officials pushed back, though their objections did little to address the court’s central findings on FDA misconduct and state sovereignty. New York Attorney General Letitia James dismissed the ruling as “yet another cruel attack on abortion access,” ignoring entirely that the FDA’s own safety review of the drug remains unfinished.
The decision is expected to be appealed, potentially setting up a landmark Supreme Court confrontation. Notably, the Court’s last mifepristone ruling in 2024 never reached the core merits, having been decided solely on standing grounds, meaning the fundamental questions about federal authority over abortion drug regulation remain unresolved. Danco Laboratories, one of the drug’s manufacturers, has already filed an emergency appeal with the Supreme Court seeking to halt the ruling while litigation continues.
For now, the court’s order restores meaningful oversight over one of the most commonly used abortion methods in the country and sets the stage for what may be the most significant abortion case to reach the Supreme Court since Dobbs.
CLICK HERE FOR FULL VERSION OF THIS STORY